STOCK TITAN
  1. Home
  2. News
  3. IRWD

Ironwood - IRWD STOCK NEWS

Welcome to our dedicated page for Ironwood news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood stock.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) is a biopharmaceutical company dedicated to creating innovative medicines that significantly improve the lives of patients. Founded in 1998, Ironwood specializes in gastrointestinal (GI) therapeutics and has a strong focus on developing and commercializing treatments for chronic conditions of the GI tract.

The company's flagship product is a medicine designed for adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This medicine, discovered and developed by Ironwood, is now fully commercialized and widely used to alleviate symptoms in patients, improving their quality of life.

Ironwood's research pipeline is robust, with multiple investigational medicines targeting both the upper and lower GI tract. The company leverages its expertise in gastrointestinal disorders and pharmacologic expertise in guanylate cyclases to develop new therapies that address unmet medical needs.

Beyond its core product, Ironwood is actively exploring new opportunities and expanding its portfolio through collaborative licenses, commercial agreements, and strategic acquisitions. These efforts aim to enhance the company's research, development, manufacturing, and marketing capabilities, thereby driving growth and innovation.

Recent achievements for Ironwood include the advancement of several clinical trials, promising data from ongoing research studies, and strategic partnerships aimed at enhancing product development and market reach. Financially, Ironwood continues to build value, achieving milestones that attract continued support from shareholders.

Ironwood Pharmaceuticals remains committed to its mission of making a difference for patients through the development of groundbreaking therapies. The company’s strong pipeline, dedicated team, and strategic initiatives position it as a leading player in the field of gastrointestinal therapeutics.

News

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance

Rhea-AI Summary
Ironwood Pharmaceuticals reports strong financial performance in 2023 with LINZESS® achieving $1.1 billion in U.S. net sales, a 7% increase year-over-year. The company also generated $443 million in revenue, mainly from LINZESS collaboration revenue. Ironwood continues to expect topline results from the STARS Phase III study of apraglutide in patients with short bowel syndrome in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
earnings
-
News

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call

Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (IRWD) will host its Q4 and full year 2023 investor update conference call and webcast on February 15, 2024. The call will be available for replay via telephone and archived on Ironwood's website for 1 year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
conferences
-
News

Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation

Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) announces new data from a Phase III study evaluating linaclotide in children and adolescents aged 6-17 years with functional constipation. The data, published in The Lancet Gastroenterology & Hepatology, highlights additional efficacy endpoints and formed the basis of the FDA approval of linaclotide for this population in June 2023. Functional constipation affects an estimated 6 million children in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
clinical trial
News

Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance

Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (IRWD) expects high-single digit percentage LINZESS® EUTRx prescription demand growth in 2024 and anticipates 2024 adjusted EBITDA of greater than $150 million. The company announced this financial guidance ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference. CEO Tom McCourt expressed confidence in the company's strategic progress and position in the GI healthcare industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
none
-
News

Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (IRWD) CEO to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. Live webcast accessible through company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
conferences
-
News

Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio

Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) has successfully completed the squeeze-out merger with VectivBio Holding AG, resulting in the cancellation and conversion of all remaining outstanding ordinary shares of VectivBio into the right to receive $17.00 per share in cash. The merger was approved by VectivBio shareholders at an extraordinary general meeting. Ironwood also completed a tender offer to purchase approximately 97.5 percent of outstanding shares, followed by the voluntary delisting of VectivBio shares from Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
acquisition
News

Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference

Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (IRWD) will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023. The live webcast can be accessed through the Investors section of the company’s website. A replay will be available for 14 days following the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
conferences
-
News

Ironwood Pharmaceuticals Reports Third Quarter 2023 Results

Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) reported 8% year-over-year growth in LINZESS® (Iinaclotide) EUTRx prescription demand, with U.S. net sales of $279 million, a 7% increase. Positive final data from STARS Nutrition for apraglutide in short bowel syndrome and colon-in-continuity was reported. Phase II study of CNP-104 in primary biliary cholangitis topline data expected in Q3 2024. Maintains Full Year 2023 Guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
earnings
-
News

Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call

Rhea-AI Summary
Ironwood Pharmaceuticals, Inc. will host its Q3 2023 investor update conference call on November 9, 2023. The call will be available for replay via telephone and the webcast will be archived on Ironwood's website for 14 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
conferences earnings
News

Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting

Rhea-AI Summary
Ironwood Pharmaceuticals presented new data at the ACG 2023 Annual Scientific Meeting and Postgraduate Course, highlighting the impact of linaclotide on symptoms of IBS-C and CIC and the burden of these disorders on patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
none

FAQ

What is the current stock price of Ironwood (IRWD)?

The current stock price of Ironwood (IRWD) is $1.61 as of February 28, 2025.

What is the market cap of Ironwood (IRWD)?

The market cap of Ironwood (IRWD) is approximately 586.5M.

What does Ironwood Pharmaceuticals specialize in?

Ironwood Pharmaceuticals specializes in creating medicines for gastrointestinal disorders, focusing on conditions like IBS-C and CIC.

What is Ironwood's flagship product?

Ironwood's flagship product is a medicine for adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

When was Ironwood Pharmaceuticals founded?

Ironwood Pharmaceuticals was founded in 1998.

What are some of Ironwood's recent achievements?

Recent achievements include advancing clinical trials, promising research data, and strategic partnerships to enhance product development and market reach.

How does Ironwood plan to expand its research and development capabilities?

Ironwood plans to expand through collaborative licenses, commercial agreements, and strategic acquisitions.

What areas does Ironwood's research pipeline target?

Ironwood's research pipeline targets both the upper and lower gastrointestinal tract.

What other conditions, besides IBS-C and CIC, is Ironwood working on?

Ironwood is also working on treatments for hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases.

How does Ironwood build value for its shareholders?

Ironwood builds value through achieving research milestones, strategic partnerships, and maintaining a strong product pipeline that attracts continued shareholder support.

Where is Ironwood Pharmaceuticals listed?

Ironwood Pharmaceuticals is listed on the NASDAQ under the symbol IRWD.

What is the company's mission?

Ironwood's mission is to create medicines that make a significant difference for patients, building value for shareholders, and empowering a passionate team.
Stock IRWD logo
Ironwood

Nasdaq:IRWD

IRWD Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

IRWD Stock Data

586.50M
156.60M
1.68%
105.2%
5.9%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
BOSTON